Taken together, these findings demonstrated that miR-16 expression suppressed cell proliferation, induced apoptosis and reduced angiogenesis of pituitary cancer through the VEGFR2/p38/NF-κB signaling pathway, thus suggesting miR-16 as a potential therapeutic target for clinical management of pituitary tumors. This evidence concerns the gene NFKB1 and pituitary tumor.